NOV 6, 2019

Influenza 2019

Influenza 2019 is now available On-Demand! Join us for this free virtual online conference as we discuss methods and strategies related to influenza, as well as explore new ideas and concepts on a global scale. This event will be packed with speaker sessions from industry experts, research poster presentations, and an exhibit hall with thought leaders from the field.

The theme for this years conference is Influenza in the past, present and future with the following tracks:

Control and Prevention Strategies for Influenza
- Influenza Vaccines
Structure and Function of the Influenza Virus
- Pathogenesis
- Types of Influenza
Impact of Influenza Beyond Outpatient and Inpatient Treatment
- Anti-Viral
- Routine Laboratory Diagnostics
2019 Epidemic and Future Pandemics

Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event. The webinars will be available for unlimited on-demand viewing.

Continuing Education

LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 14 credits.

Use #LRflu to follow the conversation!

Speakers

Adolfo Garcia-Sastre, PhD

Professor, Departments of Microbiology and Medicine, Tisch Cancer Center Icahn School of Medicine at Mount Sinai
BIOGRAPHY
Lynn Goldman, MD, MPH

Michael and Lori Milken Dean of Public Health, Milken Institute School of Public Health, The George Washington University
BIOGRAPHY
Glen Hansen, PhD

Assistant Professor, Division of Infectious Diseases, Department of Pathology & Laboratory Medicine, University of Minnesota, and Director of Clinical Microbiology, Hennepin Medical Center
BIOGRAPHY
Edward Hutchinson, PhD

Research Fellow (Centre for Virus Research), University of Glasgow
BIOGRAPHY
Rafael Medina Silva, PhD

Associate Professor, Laboratory of Molecular Virology, Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Catolica de Chile
BIOGRAPHY
Peter Palese, PhD

Professor and Chair Department of Microbiology, Professor in Department of Medicine and Infectious Diseases, Icahn School of Medicine at Mount Sinai
BIOGRAPHY
Jun Wang, PhD

Assistant Professor, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona
BIOGRAPHY

Show Resources

You May Also Like

DEC 07, 2021 12:30 PM EST

NCATS at 10: Improving Health for All Through Translational Science

Date: December 7, 2021 Time: 12:30-5:00 p.m. ET #NCATS10...

SEP 06, 2022 6:00 AM PDT

Microbiology Virtual Week 2022

LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 8th Annu...

NOV 10, 2021 6:00 AM PST

C.E. CREDITS

NOV 10, 2021 6:00 AM PST

Clinical Diagnostics & Research 2021

Twelve years ago Labroots launched a new system of learning for a global scientific audience. Now, the 2021 Clinical Diagnostics and Research Virtual Event...

NOV 09, 2022 6:00 AM PST

Clinical Diagnostics & Research 2022

Thirteen years ago Labroots launched a new system of learning for a global scientific audience. Now, the 2022 Clinical Diagnostics and Research Virtual Event will again bring together clinic...

JAN 25, 2022 1:00 AM PST

Lab Compliance Connect

Europe - 10:00 AM Central European Time United Kingdom - 10:00 AM British Summer Time North America - 10:00 AM Central Standard Time Lab Compliance Connect – The world’s leading...

APR 19, 2022 6:00 AM PDT

Genetics Virtual Week 2022

LabRoots is excited to announce our 10th Annual Genetics Virtual Week held on April 19-21, 2022! Genetics Virtual Week 2022 will offer a multi-day content-rich program combining stellar expe...

Agenda

Download Agenda

NOV 06, 2019 1:30 PM PST

Challenges towards a Universal Influenza Virus Vaccine

Peter Palese, PhD

Professor and Chair Department of Microbiology, Professor in Department of Medicine and Infectious Diseases, Icahn School of Medicine at Mount Sinai
BIOGRAPHY

Despite FDA-approved vaccines and antivirals, seasonal and pandemic influenza remains a serious threat associated with substantial morbidity and mortality. The present modalities and vaccine approaches will be discussed and the difficulties one faces with the presently available formulations will be addressed. While annual seasonal influenza virus vaccination is frequently effective – albeit underutilized in most countries – a safe universal influenza virus vaccine providing broad and long-lasting immunity would represent a major breakthrough. We have developed vaccine constructs which express chimeric hemagglutinins resulting in the redirection of the immune response away from the immunodominant (variant) head domain of the hemagglutinin toward the much more conserved stalk of the hemagglutinin and the highly conserved neuraminidase. Such vaccine constructs work well in animal challenge models and await extensive clinical trials in humans.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
NOV 06, 2019 1:30 PM PST

Impact of the cobas Liat® Flu Assay on Clinical Decision Making in the Emergency Department Setting (Clade Study Group)

Glen Hansen, PhD

Assistant Professor, Division of Infectious Diseases, Department of Pathology & Laboratory Medicine, University of Minnesota, and Director of Clinical Microbiology, Hennepin Medical Center
BIOGRAPHY

Respiratory viral infections remain a leading cause of medical visits and can contribute significantly to morbidity and mortality. Influenza, together with pneumonia, is the leading infectious cause of death in Canada and the United States, and is of particular concern especially in individuals with secondary risk factors. As "influenza season" approaches each year, hospitals and healthcare organizations review and update testing algorithms in attempts to maximize clinical useful testing, staffing issues, sensitivity, and rising health care costs. Despite decades of diagnostic research into laboratory and clinic based influenza testing, no one single diagnostic algorithm has emerged as a one size-fits-all strategy. Clinical decision making and subsequent patient management for patients who present to busy emergency departments during flu season is not always straight forward. Recently the COBAS LIAT Influenza assay was recently approved by the FDA for diagnosis of Influenza A/B virus. The test represents among the first truly rapid multiplex molecular PCR-based assays that can simultaneously detect and discriminate influenza A and influenza B RNA in nasopharyngeal specimens. While the prospects of reliable rapid influenza diagnostics have been examined before, few studies have attempted to correlate in real time the immediate impact of influenza assays, and no study assessing the clinical utility of LIAT during influenza season has been performed to date. Objectives: 1. Introduce the historical challenges of test options for influenza testing in hospital settings 2. Describe the performance and test characteristics of the Cobas® Liat influenza A/B assay on emergency department patients who presented with influenza-like-illness during the 2015 influenza season 3. Demonstrate the impact that rapid reliable influenza testing within emergency department settings have on patient management

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
NOV 06, 2019 12:00 PM PST

A dose of the flu: influenza's variable virus particles

Edward Hutchinson, PhD

Research Fellow (Centre for Virus Research), University of Glasgow
BIOGRAPHY

Influenza viruses are transmitted by membrane-bound virus particles, or virions. Unlike some viruses, which produce near-identical virions from a well-defined set of viral components, influenza virions are assembled from shifting mixtures of viral and host components and vary markedly in their size, shape and composition. In this talk we will show how a variety of advanced methods can be combined to explore the complex structure of influenza virions. We will examine sources of variation in influenza virions and discuss the challenges this variation creates for understanding how influenza viruses infect new cells.

Learning Objectives:
1. Gain a detailed understanding of the structure and composition of the virus particles that transmit influenza infections.
2. Understand that the idea of a single type of influenza virus particle is a simplification, and that in fact influenza infections involve interactions between a highly variable mixture of different particles.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
NOV 06, 2019 10:30 AM PST

Drug discovery and pharmacology of antivirals targeting drug-resistant influenza viruses

Jun Wang, PhD

Assistant Professor, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona
BIOGRAPHY

The efficacy of current influenza antiviral drugs is compromised by emerging drug resistance. To address this unmet medical need, we have made progress in developing novel influenza antivirals by targeting the drug-resistant mutants of M2 and the viral polymerase. In this presentation, I will introduce our work in designing inhibitors targeting the viral M2-S31N mutant proton channel and the viral polymerase PA-PB1 interactions. The designed M2-S31N inhibitors and the PA-PB1 inhibitors have been shown to inhibit drug resistant influenza viruses with potent antiviral efficacy and a high selectivity index.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
NOV 06, 2019 9:00 AM PST

The 2019 Flu Season: Protecting your health and the health of your family

Lynn Goldman, MD, MPH

Michael and Lori Milken Dean of Public Health, Milken Institute School of Public Health, The George Washington University
BIOGRAPHY

To prepare for the 2019 flu season it is important to get immunized. In 2019 a tetravalent (four-virus) vaccine is available in a number of forms including an egg-free formulation that is for people who have egg allergies. The talk delineates populations who are highest priority for flu vaccine as well as age-appropriate guidelines for the general population. It also is important to understand the symptoms and signs of flu – and how flu is transmitted – in order to take appropriate action to prevent spread of flu virus should one become infected

We must also be prepared for a possible flu pandemic, which occurs infrequently but can happen in any year when a new strain of flu emerges. Since flu pandemics are unpredictable it is important to have in place global capacity to monitor and investigate “novel” flu cases. The talk describes the stages of a flu pandemic and actions that are taken at each stage. Vaccines would not initially be available and in the case of a major pandemic transmission might be controlled via measures such as closing schools and workplaces and reducing travel.

Learning Objectives:
1. Understand the basics of influenza virus infection in terms of virus types; signs and symptoms indicative of flu infection; and the differences between seasonal and pandemic flu.
2. Understand the steps that can be taken to prevent seasonal influenza via immunization and other actions, and the availability of age-specific as well as egg-free flu vaccines in 2019.
3. Understand how flu pandemics arise, pandemic stages and measures that are taken to control pandemics at various stages.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
NOV 06, 2019 7:30 AM PST

Toward a universal influenza virus vaccine

Adolfo Garcia-Sastre, PhD

Professor, Departments of Microbiology and Medicine, Tisch Cancer Center Icahn School of Medicine at Mount Sinai
BIOGRAPHY

Since the establishment of reverse genetics techniques to manipulate the influenza virus genome, it has been possible to study viral molecular signatures responsible for virulence, and the generation of novel and improved vaccine strains. Moreover, high throughput screen technologies combined with functional genomics, transcriptomics and proteomics are now been used to identify novel mechanisms associated with virus replication and pathogenicity, as well as novel antivirals. Finally recombinant technologies can now be applied for the generation of broadly neutralizing influenza virus vaccines that could eliminate the need for annual vaccination and prevent pandemics by inducing protective immunity against conserved epitope shared by all influenza virus strains.

Learning objectives:

1. Current influenza vaccines and antivirals are useful, but not optimal
2. New technologies allow the discovery of improved influenza antivirals and vaccines

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
NOV 06, 2019 6:00 AM PST

Understanding the Pathogenesis of Human Influenza Virus: A Systems Virology Approach

Rafael Medina Silva, PhD

Associate Professor, Laboratory of Molecular Virology, Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Catolica de Chile
BIOGRAPHY

Multiple factors can affect and impact infection dynamics and virulence produced by influenza virus (IV) infections. Susceptibility factors and host responses can also have major effects in disease severity. It has become apparent that innate and adaptive immune responses can modulate clinical evolution to infection, which is directly and indirectly modulated by factors such as pre-existing conditions and host and virus genetic background. Thus, a major leap forward lies in understanding and integrating global virus-host interactions. To identify viral and host molecular markers of disease severity and outcome we investigated IV diversity and evolution and host responses to infection. Hence, we evaluated the status of the innate and adaptive immune responses, and established clinical parameters associated with poor outcome. A comprehensive multiscale analysis of clinical metadata and cytokine profiling, revealed that comorbidities such as arterial hypertension, chronic cardiovascular disease and obesity, together with early increased expression of pro-inflammatory cytokines, including of IL-6, 8 and the anti-inflammatory IL-10, were associated with severity. Additionally, we used next generation sequencing and developed bioinformatics tools to investigate viral diversity and to evaluate different IV variants obtained from severe individuals. We identified a number of transitional amino acid changes over time in functional sites. Notably, we found two novel mutations of epidemiological relevance in the viral glycoproteins. The I223M mutation on the Neuraminidase was found to confer resistance to the antiviral oseltamivir, whereas a K180Q residue change in a major antigenic site of the Hemagglutinin was found to contribute to the evasion of preexisting immunity (antibody responses). These changes occurred independently in severe subjects and were detected as mixed populations in sequential samples, indicating a dynamic change in the IV genome over time. Overall, our systematic approach suggests that early aberrant immune responses and increased viral diversity in susceptible individuals can play a crucial role in disease outcome. This translational virology approach allows us to interrogate complex biological systems in depth, to define and dissect the global molecular processes involved in viral infection and disease.
FUNDING: FONDECYT 1121172, 1161791 and PIA-ACT 1408 from CONICYT, the Chilean Ministry of Economy, Development and Tourism, P09/016-F, the Center for Research in Influenza Pathogenesis (CRIP) HHSN272201400008C and grant U19AI135972 both from NIH-NIAID

Learning Objectives:
1. To identify what factors can contribute to disease severity during Influenza virus infection.
2. To describe novel techniques and methodologies used to study viral-host interactions.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar

Structure and Function of the Influenza Virus
NOV 06, 2019 6:00 AM PST

Understanding the Pathogenesis of Human Influenza Virus: A Systems Virology Approach

Rafael Medina Silva, PhD

Associate Professor, Laboratory of Molecular Virology, Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Catolica de Chile
BIOGRAPHY

Multiple factors can affect and impact infection dynamics and virulence produced by influenza virus (IV) infections. Susceptibility factors and host responses can also have major effects in disease severity. It has become apparent that innate and adaptive immune responses can modulate clinical evolution to infection, which is directly and indirectly modulated by factors such as pre-existing conditions and host and virus genetic background. Thus, a major leap forward lies in understanding and integrating global virus-host interactions. To identify viral and host molecular markers of disease severity and outcome we investigated IV diversity and evolution and host responses to infection. Hence, we evaluated the status of the innate and adaptive immune responses, and established clinical parameters associated with poor outcome. A comprehensive multiscale analysis of clinical metadata and cytokine profiling, revealed that comorbidities such as arterial hypertension, chronic cardiovascular disease and obesity, together with early increased expression of pro-inflammatory cytokines, including of IL-6, 8 and the anti-inflammatory IL-10, were associated with severity. Additionally, we used next generation sequencing and developed bioinformatics tools to investigate viral diversity and to evaluate different IV variants obtained from severe individuals. We identified a number of transitional amino acid changes over time in functional sites. Notably, we found two novel mutations of epidemiological relevance in the viral glycoproteins. The I223M mutation on the Neuraminidase was found to confer resistance to the antiviral oseltamivir, whereas a K180Q residue change in a major antigenic site of the Hemagglutinin was found to contribute to the evasion of preexisting immunity (antibody responses). These changes occurred independently in severe subjects and were detected as mixed populations in sequential samples, indicating a dynamic change in the IV genome over time. Overall, our systematic approach suggests that early aberrant immune responses and increased viral diversity in susceptible individuals can play a crucial role in disease outcome. This translational virology approach allows us to interrogate complex biological systems in depth, to define and dissect the global molecular processes involved in viral infection and disease.
FUNDING: FONDECYT 1121172, 1161791 and PIA-ACT 1408 from CONICYT, the Chilean Ministry of Economy, Development and Tourism, P09/016-F, the Center for Research in Influenza Pathogenesis (CRIP) HHSN272201400008C and grant U19AI135972 both from NIH-NIAID

Learning Objectives:
1. To identify what factors can contribute to disease severity during Influenza virus infection.
2. To describe novel techniques and methodologies used to study viral-host interactions.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
NOV 06, 2019 12:00 PM PST

A dose of the flu: influenza's variable virus particles

Edward Hutchinson, PhD

Research Fellow (Centre for Virus Research), University of Glasgow
BIOGRAPHY

Influenza viruses are transmitted by membrane-bound virus particles, or virions. Unlike some viruses, which produce near-identical virions from a well-defined set of viral components, influenza virions are assembled from shifting mixtures of viral and host components and vary markedly in their size, shape and composition. In this talk we will show how a variety of advanced methods can be combined to explore the complex structure of influenza virions. We will examine sources of variation in influenza virions and discuss the challenges this variation creates for understanding how influenza viruses infect new cells.

Learning Objectives:
1. Gain a detailed understanding of the structure and composition of the virus particles that transmit influenza infections.
2. Understand that the idea of a single type of influenza virus particle is a simplification, and that in fact influenza infections involve interactions between a highly variable mixture of different particles.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
Control and Prevention Strategies for Influenza
NOV 06, 2019 7:30 AM PST

Toward a universal influenza virus vaccine

Adolfo Garcia-Sastre, PhD

Professor, Departments of Microbiology and Medicine, Tisch Cancer Center Icahn School of Medicine at Mount Sinai
BIOGRAPHY

Since the establishment of reverse genetics techniques to manipulate the influenza virus genome, it has been possible to study viral molecular signatures responsible for virulence, and the generation of novel and improved vaccine strains. Moreover, high throughput screen technologies combined with functional genomics, transcriptomics and proteomics are now been used to identify novel mechanisms associated with virus replication and pathogenicity, as well as novel antivirals. Finally recombinant technologies can now be applied for the generation of broadly neutralizing influenza virus vaccines that could eliminate the need for annual vaccination and prevent pandemics by inducing protective immunity against conserved epitope shared by all influenza virus strains.

Learning objectives:

1. Current influenza vaccines and antivirals are useful, but not optimal
2. New technologies allow the discovery of improved influenza antivirals and vaccines

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
NOV 06, 2019 1:30 PM PST

Challenges towards a Universal Influenza Virus Vaccine

Peter Palese, PhD

Professor and Chair Department of Microbiology, Professor in Department of Medicine and Infectious Diseases, Icahn School of Medicine at Mount Sinai
BIOGRAPHY

Despite FDA-approved vaccines and antivirals, seasonal and pandemic influenza remains a serious threat associated with substantial morbidity and mortality. The present modalities and vaccine approaches will be discussed and the difficulties one faces with the presently available formulations will be addressed. While annual seasonal influenza virus vaccination is frequently effective – albeit underutilized in most countries – a safe universal influenza virus vaccine providing broad and long-lasting immunity would represent a major breakthrough. We have developed vaccine constructs which express chimeric hemagglutinins resulting in the redirection of the immune response away from the immunodominant (variant) head domain of the hemagglutinin toward the much more conserved stalk of the hemagglutinin and the highly conserved neuraminidase. Such vaccine constructs work well in animal challenge models and await extensive clinical trials in humans.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
2019 Epidemic and Future Pandemics
NOV 06, 2019 9:00 AM PST

The 2019 Flu Season: Protecting your health and the health of your family

Lynn Goldman, MD, MPH

Michael and Lori Milken Dean of Public Health, Milken Institute School of Public Health, The George Washington University
BIOGRAPHY

To prepare for the 2019 flu season it is important to get immunized. In 2019 a tetravalent (four-virus) vaccine is available in a number of forms including an egg-free formulation that is for people who have egg allergies. The talk delineates populations who are highest priority for flu vaccine as well as age-appropriate guidelines for the general population. It also is important to understand the symptoms and signs of flu – and how flu is transmitted – in order to take appropriate action to prevent spread of flu virus should one become infected

We must also be prepared for a possible flu pandemic, which occurs infrequently but can happen in any year when a new strain of flu emerges. Since flu pandemics are unpredictable it is important to have in place global capacity to monitor and investigate “novel” flu cases. The talk describes the stages of a flu pandemic and actions that are taken at each stage. Vaccines would not initially be available and in the case of a major pandemic transmission might be controlled via measures such as closing schools and workplaces and reducing travel.

Learning Objectives:
1. Understand the basics of influenza virus infection in terms of virus types; signs and symptoms indicative of flu infection; and the differences between seasonal and pandemic flu.
2. Understand the steps that can be taken to prevent seasonal influenza via immunization and other actions, and the availability of age-specific as well as egg-free flu vaccines in 2019.
3. Understand how flu pandemics arise, pandemic stages and measures that are taken to control pandemics at various stages.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
Impact of Influenza Beyond Outpatient and Inpatient Treatment
NOV 06, 2019 10:30 AM PST

Drug discovery and pharmacology of antivirals targeting drug-resistant influenza viruses

Jun Wang, PhD

Assistant Professor, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona
BIOGRAPHY

The efficacy of current influenza antiviral drugs is compromised by emerging drug resistance. To address this unmet medical need, we have made progress in developing novel influenza antivirals by targeting the drug-resistant mutants of M2 and the viral polymerase. In this presentation, I will introduce our work in designing inhibitors targeting the viral M2-S31N mutant proton channel and the viral polymerase PA-PB1 interactions. The designed M2-S31N inhibitors and the PA-PB1 inhibitors have been shown to inhibit drug resistant influenza viruses with potent antiviral efficacy and a high selectivity index.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar
NOV 06, 2019 1:30 PM PST

Impact of the cobas Liat® Flu Assay on Clinical Decision Making in the Emergency Department Setting (Clade Study Group)

Glen Hansen, PhD

Assistant Professor, Division of Infectious Diseases, Department of Pathology & Laboratory Medicine, University of Minnesota, and Director of Clinical Microbiology, Hennepin Medical Center
BIOGRAPHY

Respiratory viral infections remain a leading cause of medical visits and can contribute significantly to morbidity and mortality. Influenza, together with pneumonia, is the leading infectious cause of death in Canada and the United States, and is of particular concern especially in individuals with secondary risk factors. As "influenza season" approaches each year, hospitals and healthcare organizations review and update testing algorithms in attempts to maximize clinical useful testing, staffing issues, sensitivity, and rising health care costs. Despite decades of diagnostic research into laboratory and clinic based influenza testing, no one single diagnostic algorithm has emerged as a one size-fits-all strategy. Clinical decision making and subsequent patient management for patients who present to busy emergency departments during flu season is not always straight forward. Recently the COBAS LIAT Influenza assay was recently approved by the FDA for diagnosis of Influenza A/B virus. The test represents among the first truly rapid multiplex molecular PCR-based assays that can simultaneously detect and discriminate influenza A and influenza B RNA in nasopharyngeal specimens. While the prospects of reliable rapid influenza diagnostics have been examined before, few studies have attempted to correlate in real time the immediate impact of influenza assays, and no study assessing the clinical utility of LIAT during influenza season has been performed to date. Objectives: 1. Introduce the historical challenges of test options for influenza testing in hospital settings 2. Describe the performance and test characteristics of the Cobas® Liat influenza A/B assay on emergency department patients who presented with influenza-like-illness during the 2015 influenza season 3. Demonstrate the impact that rapid reliable influenza testing within emergency department settings have on patient management

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Watch Webinar

Speakers

Adolfo Garcia-Sastre, PhD

Professor, Departments of Microbiology and Medicine, Tisch Cancer Center Icahn School of Medicine at Mount Sinai

BIOGRAPHY
Lynn Goldman, MD, MPH

Michael and Lori Milken Dean of Public Health, Milken Institute School of Public Health, The George Washington University

BIOGRAPHY
Glen Hansen, PhD

Assistant Professor, Division of Infectious Diseases, Department of Pathology & Laboratory Medicine, University of Minnesota, and Director of Clinical Microbiology, Hennepin Medical Center

BIOGRAPHY
Edward Hutchinson, PhD

Research Fellow (Centre for Virus Research), University of Glasgow

BIOGRAPHY
Rafael Medina Silva, PhD

Associate Professor, Laboratory of Molecular Virology, Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Catolica de Chile

BIOGRAPHY
Peter Palese, PhD

Professor and Chair Department of Microbiology, Professor in Department of Medicine and Infectious Diseases, Icahn School of Medicine at Mount Sinai

BIOGRAPHY
Jun Wang, PhD

Assistant Professor, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona

BIOGRAPHY

General Labroots Questions

email support@labroots.com

Virtual Events and Webinars

Supported Configurations

Operating System	Internet Explorer	Firefox	Chrome	Safari
Vista	IE8+	FF10+	Chrome15+
Windows 7	IE8+	FF10+	Chrome15+
Windows 8	IE10	FF10+	Chrome15+
Mac OS X		FF10+	Chrome15+	Safari5.1+

Cookie settings: session cookies enabled
Browser configuration must have JavaScript enabled
Adobe Flash player 10.2 or later

To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

Internet Connection

A minimum of 100Kbps is recommended for audio-only events
A minimum of 300Kbps is recommended for speaker on-video events

Computer Equipment

Screen Resolution: Minimum 1024x768
Video Card: 65,000 colors minimum
Sound card and speakers (or headphones) for hearing webcast in full format
Audio Card: 16-bit minimum
RAM: 512MB of free RAM

Firewall Protocol

HTTP on port 80 or HTTPS on port 443
Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
RTMPE (RTMP encrypted) on ports 1935, 80 or 443

Work-At-Home Attendees

If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

For A Seamless Experience

Registration is required for most events
Adobe Flash Player is needed to view webinar videos
Self Test your system compatibility ahead of time

When using a mobile device, FREE Mobile Apps are available:

- For viewing Webinars:

iPhone/iPad, download the Webcast Studio App
Android device, download the Webcast Studio App

- For viewing Virtual Events

iPhone/iPad, download the Virtual Environments App
Android, download the Virtual Environments App

Attendee Guide

To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

Virtual Event and Webinar Support:

Email: support@labroots.com
Webpage: About Virtual Events

Continuing Education (CME/CE) Support

Phone: +1-714-930-3518
Email: CE@labroots.com
Webpage: Continuing Education CME/CE Credits

Demographics

Specialty

Microbiology

Molecular Biology

Immunology

Infectious Disease

Laboratory Testing

Molecular Diagnostics

Clinical Diagnostics

Genetics

Cell Biology

Biotechnology

Cancer Research

Dna

Pcr/rt-Pcr/real-Time Pcr

Clinical Research

Biochemistry

Geography

North America66%

Asia14%

Europe11%

South America3%

Africa3%

Oceania1%

Registration Source

Website Visitors67%

Email Promotions20%

WAVE Newsletter Promotion7%

Client/Sponsor Promotions2%

Website Banners1%

Social Media Promotions1%

Trending Newsletter Promotion1%

Other1%

Job Title

Medical Laboratory Technician21%

Student14%

Clinical Laboratory Scientist10%

Lab Management8%

Facility/Department Manager8%

Medical Doctor/Specialist7%

Research Scientist7%

Educator/Faculty7%

Executive6%

Scientist4%

Microbiologist3%

QC/QA2%

Post Doc2%

Biologist2%

Organization

Academic Institution21%

Hospital21%

Clinical Laboratory15%

Biotech Company5%

Medical Center4%

Research Institute3%

Government3%

Medical School3%

Pharmaceutical Company2%

Diagnostic Company2%

Government/public2%

Non-Profit Organization2%

Medical Device Company1%

Independent Laboratories1%

Other5%